Atara Biotherape Stock Price, News & Analysis

Atara Biotherapeutics (NASDAQ: ATRA) announced that CEO Pascal Touchon will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 3:45 PM PST in San Francisco. The company specializes in T-cell immunotherapy, focusing on treatments for cancer and autoimmune diseases, utilizing its allogeneic EBV T-cell platform. A live audio webcast of the presentation will be accessible on their website, along with an archived replay available for 30 days post-event.

Atara Biotherapeutics (ATRA) has secured a $31 million royalty interest financing agreement with HealthCare Royalty for its therapy, Ebvallo™, in Europe. This agreement is expected to extend Atara's cash runway and includes specified royalties and milestones linked to its commercialization partnership with Pierre Fabre. Additional milestones of $40 million from Pierre Fabre are also anticipated. The deal is seen as a strategic move to bolster Atara's financial position following the recent European approval of Ebvallo™ for treating a rare cancer.

Atara Biotherapeutics, Inc. announced that Carol Gallagher will replace Ron Renaud as Chair of the Board of Directors. Gallagher, a seasoned public company director, brings extensive experience, having served on Atara's Board since 2013. Renaud stepped down to focus on his new role at Bain Capital Life Sciences. Additionally, Roy Baynes will also leave the Board to pursue other opportunities. Atara’s President, Pascal Touchon, expressed confidence in Gallagher's leadership as the company continues to develop its EBV T-cell therapies aimed at serious diseases.

Atara Biotherapeutics (NASDAQ: ATRA) receives European Commission approval for Ebvallo™ (tabelecleucel) to treat patients with EBV+ PTLD. This marks the first approval of an allogeneic T-cell immunotherapy globally.

Ebvallo™ is indicated for patients aged over two years with relapsed or refractory EBV+ PTLD who have had prior therapy. The approval comes after a positive opinion from the EMA’s CHMP, based on pivotal Phase 3 ALLELE study results.

Pierre Fabre will handle commercialization in Europe, benefiting patients facing a median survival of less than four months.

Atara Biotherapeutics announced interim results from its Phase 3 ALLELE study of tabelecleucel (tab-cel) for treating relapsed/refractory EBV+ PTLD. The study showed a 51.2% objective response rate in 43 patients, with a median duration of response of 23.0 months and median overall survival of 18.4 months. Results were presented at the 64th American Society of Hematology Annual Meeting. Tab-cel demonstrated potential in treating previously unaddressed EBV+ conditions, suggesting a significant market opportunity for Atara.

Atara Biotherapeutics (NASDAQ: ATRA) has announced the grant of 33,150 restricted stock units and 13,375 stock options to newly hired employees, aimed at incentivizing talent. The restricted stock units will vest over four years, while the stock options have a ten-year term with an exercise price set at $4.40. This action aligns with Nasdaq Listing Rule 5635(c)(4) to attract employees critical for the company's focus on T-cell immunotherapy. Atara continues to push forward its EBV T-cell platform for treating serious diseases.

Atara Biotherapeutics (NASDAQ: ATRA) announced that its CEO, Pascal Touchon, will engage in a virtual fireside chat at the Evercore ISI 5th Annual HealthCONx Conference on November 30, 2022, at 2:15 p.m. EST. The event will focus on Atara's advancements in T-cell immunotherapy, particularly its allogeneic Epstein-Barr virus (EBV) T-cell platform. Attendees can access a live webcast on atarabio.com, with an archived version available for 30 days post-event.

Atara Biotherapeutics (NASDAQ: ATRA) announced that its Chief Medical Officer, AJ Joshi, and Chief Financial Officer, Utpal Koppikar, will participate in a fireside chat at the Stifel Healthcare Conference in New York on November 16, 2022, at 1:50 p.m. EST. A live webcast will be available on atarabio.com, with an archived replay accessible for 30 days. Atara is pioneering T-cell immunotherapy targeting conditions like cancer and autoimmune diseases, leveraging its unique allogeneic Epstein-Barr virus T-cell platform.

Atara Biotherapeutics reported significant progress in T-cell immunotherapy, highlighted by a positive CHMP opinion for its product Ebvallo™ for treating EBV+ PTLD. The EMA's endorsement positions it as the first allogeneic T-cell therapy potentially approved by the end of 2022. Financially, Atara reported a net loss of $84.1 million, with cash reserves of $265.4 million as of September 30, 2022. The company also presented promising data on ATA188 for progressive MS, showing less brain atrophy and potential remyelination. A conference call is scheduled for November 8, 2022.